These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38328413)

  • 1. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
    Fadini GP; Longato E; Morieri ML; Del Prato S; Avogaro A; Solini A;
    Lancet Reg Health Eur; 2024 Mar; 38():100847. PubMed ID: 38328413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study.
    Forbes AK; Hinton W; Feher MD; Elson W; Joy M; Ordóñez-Mena JM; Fan X; Cole NI; Banerjee D; Suckling RJ; de Lusignan S; Swift PA
    EClinicalMedicine; 2024 Feb; 68():102426. PubMed ID: 38304744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
    Heerspink HJL; Kiyosue A; Wheeler DC; Lin M; Wijkmark E; Carlson G; Mercier AK; Åstrand M; Ueckert S; Greasley PJ; Ambery P
    Lancet; 2023 Nov; 402(10416):2004-2017. PubMed ID: 37931629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan.
    Tangri N; Rastogi A; Nekeman-Nan C; Hong LS; Ozaki A; Franzén S; Sofue T
    Adv Ther; 2024 Mar; 41(3):1151-1167. PubMed ID: 38240949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
    Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
    J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
    Groop PH; Dandona P; Phillip M; Gillard P; Edelman S; Jendle J; Xu J; Scheerer MF; Thoren F; Iqbal N; Repetto E; Mathieu C
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):845-854. PubMed ID: 32946821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
    Schechter M; Melzer Cohen C; Fishkin A; Rozenberg A; Yanuv I; Sehtman-Shachar DR; Chodick G; Clark A; Abrahamsen TJ; Lawson J; Karasik A; Mosenzon O
    Cardiovasc Diabetol; 2023 May; 22(1):126. PubMed ID: 37244998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.
    Jongs N; Chertow GM; Greene T; McMurray JJV; Langkilde AM; Correa-Rotter R; Kashihara N; Rossing P; Sjöström CD; Stefánsson BV; Toto RD; Wheeler DC; Heerspink HJL; ;
    J Am Soc Nephrol; 2022 Nov; 33(11):2094-2107. PubMed ID: 35977807
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Yoshihara F; Imazu M; Sakuma I; Hiroi Y; Hara H; Okazaki O; Ishiguro C; Izumi C; Noguchi T; Shiraiwa T; Nishioka N; Fujii K; Iwakura K; Tomonaga O; Kobayashi K; Takihata M; Yumoto K; Takase H; Himi T; Shimizu I; Murakami T; Wagatsuma K; Sato K; Hiramatsu T; Akabame S; Hata S; Asakura M; Kawabata T; Omae K; Ito S; Kitakaze M;
    EClinicalMedicine; 2023 Dec; 66():102334. PubMed ID: 38192595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.
    Fadini GP; Solini A; Manca ML; Penno G; Gatti A; Anichini R; Del Prato S; Avogaro A;
    Diabetes Obes Metab; 2019 Feb; 21(2):252-260. PubMed ID: 30136354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
    Wheeler DC; Jongs N; Stefansson BV; Chertow GM; Greene T; Hou FF; Langkilde AM; McMurray JJV; Rossing P; Nowicki M; Wittmann I; Correa-Rotter R; Sjöström CD; Toto RD; Heerspink HJL;
    Nephrol Dial Transplant; 2022 Aug; 37(9):1647-1656. PubMed ID: 34850160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.